久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國Mylan Labs
MYLAN公司始建于1961年，總部設在美國賓夕法尼亞州匹茲堡市，公司股票在美國紐約證券交易所上市。MYLAN的產品范圍涵蓋普藥、專利藥和醫藥原料，品種多達570多種，是全球領先的非專利藥和特效藥生產商之一。MYLAN公司在2007年5月收購了印度MATRIX集團，并于同年10月完成了令世界制藥行業矚目的并購——以50億歐元收購了全球第二大跨國公司——默克公司的通用名藥物部門，從而躋身為全球第二大原料藥供應商和第三大跨國性的非專利藥品生產商。MYLAN的商業領域遍布全球90多個國家，目前員工遍布全球各大洲，人數超過12000人。2007年MYLAN的銷售額近48億美元。

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 140 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. With approximately 15,500 employees, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale and a committed focus on quality and customer service. The company ranks among the top five generics companies in several markets around the world and is the largest U.S.-based generics manufacturer in the world.

Through its subsidiary Matrix Laboratories, Mylan has direct access to one of the world’s largest active pharmaceutical ingredient (API) manufacturers. This relationship makes Mylan one of only two global generics companies with a comprehensive, vertically integrated supply chain. Matrix also is one of the world’s largest producers of API used to make generic antiretroviral (ARV) therapies for the treatment of HIV/AIDS.

Additionally, Mylan operates a fully integrated specialty pharmaceutical business, Dey Pharma, which produces innovative medicinal therapies, including EpiPen? Auto-Injector.
?